Entera Bio Ltd., a clinical-stage company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and streamed online, providing insights into Entera's innovative oral treatments for osteoporosis and other conditions. This participation highlights Entera's progress and commitment to advancing its pipeline, including its lead product EB613, an oral osteoporosis treatment currently in Phase 2 trials.
Ondo Finance launched its perpetual DEX trading platform less than a month ago, and its daily trading volume has more than doubled from $128 million to over $300 million, pushing cumulative volume close to $6 billion. This growth is notable as it occ...
Balchem Corporation reported Q2 earnings with an EPS of $1.49, beating estimates by $0.07 and exceeding revenue consensus by $15 million, showing an 11% year-over-year increase. All business segments grew, with revenue gains ranging from 8.9% to 15%,...
FIGS, Inc. has been upgraded from a sell to a hold rating following a 16% decline in its share price, which now reflects fair value. The company reported a 28% year-over-year revenue increase in Q1 2026, driven by a 12% rise in active customers and h...
Uber Technologies has underperformed the market recently due to concerns about risks from self-driving vehicle development. Despite this, Uber maintains strong business fundamentals, diversified services, and attractive growth and profitability prosp...
Climb Global Solutions, Inc. reported mixed results for Q2, showing strong revenue growth driven by existing and new software vendors. However, profitability declined due to increased selling, general, and administrative expenses. The company faces l...
